AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item: http://hdl.handle.net/11055/619
Title: The Effectiveness and Safety of Tranexamic Acid in Orthotopic Liver Transplantation Clinical Practice: A Propensity Score Matched Cohort Study
Authors: Badenoch Adam
Sharma Anand
Gower Simon
Selzner Markus
Srinivas Coimbatore
Wąsowicz Marcin
McCluskey Stuart A.
ANZCA/FPM Author: Badenoch, A
Gower, S
Keywords: Antifibrinolytic Agents/adverse effects
Antifibrinolytic Agents/therapeutic use*
Blood Loss, Surgical/prevention & control*
Databases, Factual
Erythrocyte Transfusion
Liver Transplantation*/adverse effects
Logistic Models
Postoperative Hemorrhage/etiology
Postoperative Hemorrhage/prevention & control*
Propensity Score
Retrospective Studies
Risk Assessment
Risk Factors
Thromboembolism/chemically induced
Time Factors
Tranexamic Acid/adverse effects
Tranexamic Acid/therapeutic use*
Treatment Outcome
Issue Date: Jul-2017
Citation: 101(7):1658-1665
Abstract: Background. Randomized trials have demonstrated the efficacy of tranexamic acid (TXA) in reducing blood loss and transfusion requirements during liver transplantation. However, clinical utilization is limited due to a perceived lack of generalizable effectiveness and concerns regarding its thromboembolic risks. The aim of this study was to describe the clinical use of TXA and to provide a pragmatic reappraisal of its effectiveness and safety. Methods. After ethics approval, data were collected from 1799 consecutive liver transplant recipients between January 1, 2002, and December 31, 2015, using retrospectively collected electronic databases. Propensity matching was used to account for confounders of transfusion and thrombotic risk. Exposure was defined as a total TXA dose greater than 10 mg/kg for 50% of the operative duration. Results. After propensity matching, 367 unique pairs were well balanced in terms of all measured covariates. In the matched pairs, patients exposed to TXA received less red blood cell (3 [0, 6] vs 4 [1, 7] P = 0.003) and frozen plasma (6 [2, 10] vs 6 [2, 12], P = 0.032) transfusions. There were no differences in thromboembolic events between the groups (22 [6.0%] vs 36 [9.8%]). Conclusions. TXA appears effective in reducing red blood cell transfusion requirements without increasing the risk of thromboembolic events across a wide variety of liver transplant recipients, including those at low risk of bleeding or high risk of thromboembolic complications. We did not detect evidence of an increased risk of thrombotic complications with TXA exposure.
URI: http://hdl.handle.net/11055/619
DOI: 10.1097/TP.0000000000001682
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/28187013
ISSN: 0041-1337/1534-6080
Journal Title: Transplantation
Type: Journal Article
Affiliates: Toronto General Hospital, University Health Network, University of Toronto, Ontario, Canada
Australian and New Zealand College of Anaesthetists
Study/Trial: Cohort Study
Appears in Collections:Scholarly and Clinical

Files in This Item:
File Description SizeFormat 
TXA 2017.pdf
  Restricted Access
Main Article320.47 kBAdobe PDFView/Open Request a copy
TXA 2017 Supplemental digital content.pdf
  Restricted Access
Supplementary Digital Content (Appendix)235.68 kBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.